Molecular classification of aggressive B-cell lymphoma

Molecular classification of aggressive B-cell lymphoma

Bibliographic Details
Main Authors:	Kamil Bojarczuk, Björn Chapuy
Format:	Article
Language:	English
Published:	Wiley 2019-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000273

Similar Items

Patient-Specific Modeling of Diffuse Large B-Cell Lymphoma
by: Kirsten Thobe, et al.
Published: (2021-11-01)

Editorial: The molecular landscape and promising therapeutic targets in aggressive B-cell non-Hodgkin lymphomas
by: Hanno Maximilian Witte, et al.
Published: (2023-08-01)

Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group
by: Karin Hohloch, et al.
Published: (2020-07-01)

Aggressive B-cell lymphoma subtyping: a pathologists viewpoint
by: Daphne de Jong
Published: (2019-06-01)

Current trends in pediatric aggressive B-cell lymphomas treatment
by: Yu. S. Korkina, et al.
Published: (2021-06-01)

Molecular Update and Evolving Classification of Large B-Cell Lymphoma
by: Arantza Onaindia, et al.
Published: (2021-07-01)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
by: A. Ortuzar Pasalodos, et al.
Published: (2022-06-01)

Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
by: Núria Profitós-Pelejà, et al.
Published: (2022-02-01)

Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era
by: Cheng Huang, et al.
Published: (2024-01-01)

Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas
by: Ivonne Vazquez, et al.
Published: (2020-04-01)

Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37
by: Rens Peeters, et al.
Published: (2022-09-01)

High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients
by: Dario Marino, et al.
Published: (2022-01-01)

PB2137: INFLUENCE OF PREVIOUS RADIOTHERAPY ON THE EFFECT OF CART CELL THERAPY IN AGGRESSIVE B-CELL LYMPHOMA
by: F. Shaomei
Published: (2022-06-01)

P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS
by: A. Bock, et al.
Published: (2022-06-01)

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
by: Lorenz Thurner, et al.
Published: (2023-07-01)

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
by: Hans, C, et al.
Published: (2004)

PB2101: TREATMENT OF AGGRESSIVE B-CELL LYMPHOMA WITH DA-EPOCH-R, A SINGLE CENTRE EXPERIENCE
by: E.-K. Dimitraki, et al.
Published: (2022-06-01)

MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)
by: Maria Chiara Tisi, et al.
Published: (2019-12-01)

Low lymphocyte‐to‐monocyte ratio predicts poor outcome in high‐risk aggressive large B‐cell lymphoma
by: Heli Vajavaara, et al.
Published: (2022-08-01)

Genome wide exploration of the methylome in aggressive B-cell lymphoma in Golden Retrievers reveals a conserved hypermethylome
by: Shirley Chu, et al.
Published: (2022-12-01)

Case Series of Hepatosplenic T-Cell Lymphoma: A Rare and Aggressive Disease
by: Yea Bing Tham, et al.
Published: (2023-09-01)

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
by: Kizhakeyil, A, et al.
Published: (2021)

MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas
by: Marthe Minderman, et al.
Published: (2023-03-01)

Classification of B-Cell Lymphomas and Immunodeficiency-Related Lymphoproliferations: What’s New?
by: Amy Chadburn, et al.
Published: (2023-01-01)

Molecular Characterization of Primary Mediastinal Large B-Cell Lymphomas
by: Marie Donzel, et al.
Published: (2023-10-01)

Harnessing the Molecular Fingerprints of B Cell Lymphoma for Precision Therapy
by: Afua Adjeiwaa Mensah, et al.
Published: (2022-10-01)

Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma
by: Ningwen Li, et al.
Published: (2024-02-01)

Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy
by: A. Vera de Jonge, et al.
Published: (2020-10-01)

miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication
by: Teresa Fuertes, et al.
Published: (2023-10-01)

The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma
by: Susann Schönefeldt, et al.
Published: (2021-12-01)

Primary Cutaneous Gamma-Delta T-cell Lymphoma: Not an Aggressive Disease in All Cases
by: Mehdi Khallaayoune, et al.
Published: (2020-01-01)

Natural killer cell T-cell lymphoma (nasal type), a rare and aggressive type of non-Hodgkin's lymphoma: Case report
by: Devraj Kandel, MD, et al.
Published: (2023-11-01)

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
by: Maria Patra-Kneuer, et al.
Published: (2023-07-01)

Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma
by: Ying Shang, et al.
Published: (2023-12-01)

Effect of steroid treatment on the diagnostic yield of baseline 18f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma
by: Karyn Revital Geiger, et al.
Published: (2022-09-01)

Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas
by: Stefano A. Pileri, et al.
Published: (2021-03-01)

Primary Cutaneous B-Cell Lymphoma: An Update on Pathologic and Molecular Features
by: Marco Lucioni, et al.
Published: (2022-05-01)

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
by: M. Szmyra, et al.
Published: (2022-06-01)

Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2
by: Verena Barbarino, et al.
Published: (2020-08-01)

P1384: MULTI-EFFECTOR IMMUNE CELL RETARGETING USING A BISPECIFIC SINGLE-CHAIN VARIABLE FRAGMENT LIBRARY IN AGGRESSIVE B CELL LYMPHOMAS
by: Max Freihammer, et al.
Published: (2023-08-01)